A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years.
Administrative databases
Burden of disease
Italy
Observational study
Pharmacoepidemiology
Real-world evidence
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
27 Jun 2019
27 Jun 2019
Historique:
received:
05
04
2019
accepted:
21
06
2019
entrez:
29
6
2019
pubmed:
30
6
2019
medline:
17
10
2019
Statut:
epublish
Résumé
Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4-9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10-14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use. Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM). This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.
Sections du résumé
BACKGROUND
BACKGROUND
Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population.
METHODS
METHODS
A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4-9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10-14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use.
RESULTS
RESULTS
Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM).
CONCLUSIONS
CONCLUSIONS
This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.
Identifiants
pubmed: 31248360
doi: 10.1186/s10194-019-1027-7
pii: 10.1186/s10194-019-1027-7
pmc: PMC6734283
doi:
Substances chimiques
Tryptamines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Références
Cephalalgia. 2005 Mar;25(3):214-8
pubmed: 15689197
Neurology. 2007 Jan 30;68(5):343-9
pubmed: 17261680
Scand J Public Health. 2007;35(4):424-31
pubmed: 17786807
J Headache Pain. 2008 Apr;9(2):71-6
pubmed: 18317865
Headache. 2008 Sep;48(8):1157-68
pubmed: 18808500
Headache. 2009 Mar;49(3):386-94
pubmed: 19220501
Mayo Clin Proc. 2009 May;84(5):422-35
pubmed: 19411439
Cephalalgia. 2009 Dec;29(12):1285-93
pubmed: 19438916
J Headache Pain. 2010 Aug;11(4):289-99
pubmed: 20473702
BMC Public Health. 2011 Sep 05;11:688
pubmed: 21892946
J Clin Epidemiol. 2012 Feb;65(2):126-31
pubmed: 22075111
Eur J Neurol. 2012 May;19(5):703-11
pubmed: 22136117
J Headache Pain. 2012 May;13 Suppl 2:S31-70
pubmed: 22581120
Neurol Sci. 2012 May;33 Suppl 1:S181-3
pubmed: 22644199
J Headache Pain. 2012 Jul;13(5):361-78
pubmed: 22644214
Headache. 2012 Nov-Dec;52(10):1456-70
pubmed: 22830411
Neuropsychiatr Dis Treat. 2013;9:709-20
pubmed: 23717045
Cephalalgia. 2015 Jun;35(7):619-26
pubmed: 25246521
Headache. 2015 Mar;55 Suppl 2:103-22; quiz 123-6
pubmed: 25662743
Cephalalgia. 2015 Nov;35(13):1172-80
pubmed: 25667299
Headache. 2015 Jun;55(6):778-93
pubmed: 25877672
J Headache Pain. 2015;17:48
pubmed: 27146068
Pain Pract. 2017 Jul;17(6):747-752
pubmed: 27622427
Acta Neurol Scand. 2017 Aug;136(2):155-159
pubmed: 28093722
J Pain Res. 2017 Sep 29;10:2319-2329
pubmed: 29033605
N Engl J Med. 2017 Nov 30;377(22):2190-2191
pubmed: 29171812
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
J Headache Pain. 2018 Feb 1;19(1):10
pubmed: 29392600
Neurol Sci. 2018 May;39(5):933-937
pubmed: 29468419
Lancet. 2018 Mar 31;391(10127):1315-1330
pubmed: 29523342
Neurotherapeutics. 2018 Apr;15(2):336-345
pubmed: 29616493
Neurol Sci. 2018 Jul;39(7):1169-1174
pubmed: 29637449
Cardiovasc Drugs Ther. 2018 Jun;32(3):281-286
pubmed: 29869189
Neurol Sci. 2018 Jun;39(Suppl 1):141-142
pubmed: 29904882
Expert Opin Pharmacother. 2019 Feb;20(2):209-218
pubmed: 30475090
Curr Med Res Opin. 2019 Mar 29;:1-10
pubmed: 30924392